Related Experiment Video
Updated: May 25, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Novel LDL-oriented pharmacotherapeutical strategies
1State Key Laboratory for Bioactive Substances and Functions of Natural Medicines & Ministry of Health, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanwei Road A2, Beijing 100050, PR China.
Pharmacological Research
|February 7, 2012
Summary
High LDL-C increases cardiovascular disease risk. New drugs are needed as some patients don't reach cholesterol targets with current medications, offering hope for better management.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Elevated low-density lipoprotein cholesterol (LDL-C) is a major risk factor for cardiovascular diseases (CVD).
- Current treatment guidelines emphasize lowering LDL-C to prevent CVD.
- Some high-risk patients do not achieve target LDL-C levels with existing therapies.
Purpose of the Study:
- To review current and emerging drugs for lowering LDL-C.
- To highlight the need for novel pharmaceutical strategies in hyperlipidemia management.
Main Methods:
- Literature review of existing and investigational LDL-C lowering agents.
- Categorization of emerging drugs based on their mechanisms of action.
Main Results:
- Current agents include statins, niacin, bile acid sequestrants, ezetimibe, fibrates, and omega-3 fatty acids.
- Emerging drugs target cholesterol biosynthesis, lipoprotein assembly, clearance, intestinal absorption, and enterohepatic circulation.
- Several novel agents are in clinical trials for antihyperlipidemic therapy.
Conclusions:
- Novel therapeutic strategies are essential for patients unresponsive to current treatments.
- New monotherapies or combination therapies hold promise for optimizing LDL-C levels.
- A new era of improved LDL-C management is anticipated with these advancements.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...